ERBB2 and neoplasm: In two phase 1 studies in HER2-positive breast cancers (ACE-Breast-01) and solid tumors (ACE-Pan tumor-01), ARX788 showed an ORR of 74% (14/19) and 67% (2/3), respectively [172,173].